Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Emgality (galcanezumab-gnlm) for the Treatment of Episodic Cluster Headache

drugsJune 06, 2019

Tag: FDA , Emgality , episodic , cluster , headache

PharmaSources Customer Service